Results 131 to 140 of about 1,970,330 (303)

Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields

open access: yesAdvanced Science, EarlyView.
Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng   +71 more
wiley   +1 more source

Malaria immunology and vaccine development

open access: yes, 2008
This thesis describes work undertaken by the author at the University of Oxford. Itbegins by providing an introduction to malaria infection and pathophysiology, anda review of the latest attempts to produce an effective malaria vaccine.
Thompson, Fiona Mary
core   +1 more source

Vaccination with DNA encoding cysteine proteinase confers protective immune response to rats infected with Clonorchis sinensis

open access: yes, 2006
Cysteine proteinases of C. sinensis are important virulence factors that induce pathological changes associated with larval migration and localized biliary epithelial destruction.
용태순
core   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

open access: yesAdvanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu   +7 more
wiley   +1 more source

COVID-19 vaccine development pipeline

open access: yes, 2020
A COVID-19 vaccine development tracker, developed by the Vaccine Centre at the London School of Hygiene & Tropical Medicine, that follows COVID-19 vaccine candidates as they progress through the development ...
Vaccine Centre
core   +2 more sources

Editorial: Advances in T Cell Therapeutic Vaccines for HIV

open access: yesFrontiers in Immunology, 2022
Bernard J. C. Macatangay   +3 more
doaj   +1 more source

Non‐natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity [PDF]

open access: yes
Glycopeptides derived from the glycoprotein mucin-1 (MUC1) have shown potential as tumor-associated antigens for cancer vaccine development. However, their low immunogenicity and non-selective conjugation to carriers present significant challenges for ...
Lazaris, Foivos S. [0000-0003-4292-8723]   +8 more
core   +1 more source

Disease‐Stage Synchronized Nanozyme Therapy for Polymicrobial Sepsis through Adaptive Catalytic and Immune Reprogramming

open access: yesAdvanced Science, EarlyView.
A disease‐stage synchronized nanozyme platform is developed to treat polymicrobial sepsis by adapting its functions to changing infection environments. The system eliminates multidrug‐resistant bacteria during early infection while reducing inflammation and restoring immune balance during recovery, providing an integrated strategy for infection control
Anlai Zou   +11 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy